Zhen‐Zhen Yan, Yong‐Ping Huang, Xin Wang, Hai‐Ping Wang, Fei Ren, Rui‐Feng Tian, Xu Cheng, Jie Cai, Yan Zhang, Xue‐Yong Zhu, Zhi‐Gang She, Xiao‐Jing Zhang, Zan Huang, Hongliang Li – 11 May 2019 – Hepatic ischemia‐reperfusion (IR) injury is the leading cause of liver dysfunction and failure after liver resection or transplantation and lacks effective therapeutic strategies. Here, we applied a systematic proteomic analysis to identify the prominent contributors to IR‐induced liver damage and promising therapeutic targets for this condition.

Narendra S. Choudhary, Sanjiv Saigal, Neeraj Saraf, Arvinder S. Soin – 11 May 2019

Peter Stärkel, Bernd Schnabl, Sophie Leclercq, Mina Komuta, Ramon Bataller, Josepmaria Argemi, Elena Palma, Shilpa Chokshi, Claus Hellerbrand, Luca Maccioni, Nicolas Lanthier, Isabelle Leclercq – 10 May 2019 – Mechanisms underlying alcohol‐induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce.

Peter Stärkel, Bernd Schnabl, Sophie Leclercq, Mina Komuta, Ramon Bataller, Josepmaria Argemi, Elena Palma, Shilpa Chokshi, Claus Hellerbrand, Luca Maccioni, Nicolas Lanthier, Isabelle Leclercq – 10 May 2019 – Mechanisms underlying alcohol‐induced liver injury and its progression still remain incompletely understood. Animal models can only address some aspects of the pathophysiology that requires studies directly in humans, which are scarce.

NAFLD is an increasing public health crisis. Although there are no FDA approved medications for the treatment of NAFLD, it is well established that weight loss can improve the metabolic and histologic parameters associated with NAFLD. This webinar will identify key lifestyle changes, pharmacotherapy, and the role of bariatric surgery in obesity management in patients with NAFLD.

Monday O. Ogese, Rosalind E. Jenkins, Kareena Adair, Arun Tailor, Xiaoli Meng, Lee Faulkner, Bright O. Enyindah, Amy Schofield, Rafael Diaz‐Nieto, Lorenzo Ressel, Gina L. Eagle, Neil R. Kitteringham, Chris E. Goldring, B. Kevin Park, Dean J. Naisbitt, Catherine Betts – 9 May 2019 – Idiosyncratic drug‐induced liver injury (DILI) is a rare, often difficult‐to‐predict adverse reaction with complex pathomechanisms. However, it is now evident that certain forms of DILI are immune‐mediated and may involve the activation of drug‐specific T cells.

Feng Zhou, Jianghua Zhou, Wenxin Wang, Xiao‐Jing Zhang, Yan‐Xiao Ji, Peng Zhang, Zhi‐Gang She, Lihua Zhu, Jingjing Cai, Hongliang Li – 9 May 2019 – With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis.

Na Shang, Hao Wang, Thomas Bank, Aldeb Perera, Cara Joyce, Gina Kuffel, Michael J. Zilliox, Scott J. Cotler, Xianzhong Ding, Asha Dhanarajan, Peter Breslin, Wei Qiu – 9 May 2019 – There is an urgent need to understand the molecular signaling pathways that drive or mediate the development of hepatocellular carcinoma (HCC). The focal adhesion kinase (FAK) gene protein tyrosine kinase 2 is amplified in 16.4% of The Cancer Genome Atlas HCC specimens, and its amplification leads to increased FAK mRNA expression.

Nidhi Jalan‐Sakrikar, Thiago M. De Assuncao, Guang Shi, Sayed Obaidullah Aseem, Cheng Chi, Vijay H. Shah, Robert C. Huebert – 9 May 2019 – During biliary disease, cholangiocytes become activated by various pathological stimuli, including transforming growth factor β (TGF‐β). The result is an epigenetically regulated transcriptional program leading to a pro‐fibrogenic microenvironment, activation of hepatic stellate cells (HSCs), and progression of biliary fibrosis.

Elliot B. Tapper, Shengchen Hao, Menghan Lin, John N. Mafi, Heather McCurdy, Neehar D. Parikh, Anna S. Lok – 7 May 2019 – Cirrhosis is morbid and increasingly prevalent, yet the U.S. health care system lacks enough physicians and specialists to adequately manage patients with cirrhosis. Although advanced practice providers (APPs) can expand access to cirrhosis‐related care, their impact on the quality of care remains unknown.